The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2026

Filed:

Jun. 18, 2021
Applicant:

Ac Immune SA, Lausanne, CH;

Inventors:

Emanuele Gabellieri, Le mont sur Lausanne, CH;

Jérôme Molette, Prévessin-Moëns, FR;

Véronique Dehlinger, Morges, CH;

Assignee:

AC IMMUNE SA, Lausanne, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 263/28 (2006.01); C07C 335/16 (2006.01); C07D 213/55 (2006.01); C07D 213/64 (2006.01); C07D 233/58 (2006.01); C07D 261/08 (2006.01); C07D 309/06 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01);
U.S. Cl.
CPC ...
C07D 263/28 (2013.01); C07C 335/16 (2013.01); C07D 213/55 (2013.01); C07D 213/64 (2013.01); C07D 233/58 (2013.01); C07D 261/08 (2013.01); C07D 309/06 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01);
Abstract

The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the component of the inflammasome pathway is a NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the capability to modulate the NLRP3 inflammasome pathway. Further, the compounds of the present invention are suitable for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation, in particular decrease, IL-1 beta and/or IL-18 levels.


Find Patent Forward Citations

Loading…